Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortization of Deferred Charges (2019 - 2022)

Viking Therapeutics' Amortization of Deferred Charges history spans 4 years, with the latest figure at $77000.0 for Q1 2022.

  • For Q1 2022, Amortization of Deferred Charges rose 6.94% year-over-year to $77000.0; the TTM value through Mar 2022 reached $301000.0, up 7.12%, while the annual FY2021 figure was $296000.0, 6.86% up from the prior year.
  • Amortization of Deferred Charges for Q1 2022 was $77000.0 at Viking Therapeutics, up from $76000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $77000.0 in Q1 2022 and bottomed at $64000.0 in Q1 2019.
  • The 4-year median for Amortization of Deferred Charges is $70000.0 (2020), against an average of $70000.0.
  • The largest annual shift saw Amortization of Deferred Charges grew 7.58% in 2020 before it grew 5.88% in 2021.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $66000.0 in 2019, then increased by 7.58% to $71000.0 in 2020, then increased by 7.04% to $76000.0 in 2021, then rose by 1.32% to $77000.0 in 2022.
  • Per Business Quant, the three most recent readings for VKTX's Amortization of Deferred Charges are $77000.0 (Q1 2022), $76000.0 (Q4 2021), and $75000.0 (Q3 2021).